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ABSTRACT
Background
Recent circumstantial evidence suggests that an increasing number of Iranian patients with
cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line
of treatment in Iran. This study was designed to determine whether the clinical responses
(healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to
Glucantime.
Methods and Findings
In vitro susceptibility testing was first performed on 185 isolated parasites in the intracellular
mouse peritoneal macrophage model. A strong correlation between the clinical outcome and
the in vitro effective concentration 50% (EC50) values was observed. Parasites derived from
patients with non-healing lesions had EC50 values at least 4-fold higher than parasites derived
from lesions of healing patients. A selection of these strains was typed at the molecular level by
pulsed-field gels and by sequencing the pteridine reductase 1 (PTR1) gene. These techniques
indicated that 28 out of 31 selected strains were Leishmania tropica and that three were
Leishmania major. The L. major isolates were part of a distinct pulsed-field group, and the L.
tropica isolates could be classified in three related additional pulsed-field groups. For each
pulsed-field karyotype, we selected sensitive and resistant parasites in which we transfected
the firefly luciferase marker to assess further the in vitro susceptibility of field isolates in the
monocyte cell line THP1. These determinations confirmed unequivocally that patients with
non-healing lesions were infected with L. tropica parasites resistant to Glucantime. Additional
characterization of the resistant isolates showed that resistance is stable and can be reversed by
buthionine sulfoximine, an inhibitor of glutathione biosynthesis.
Conclusions
To the authors’ knowledge, this is the first report of proven resistant parasites contributing to
treatment failure for cutaneous leishmaniasis and shows that primary Glucantime-resistant L.
tropica field isolates are now frequent in Iran.
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PLoS MEDICINEIntroduction
The protozoan parasite Leishmania is responsible for several
pathologies collectively known as leishmaniases. The cuta-
neous, mucocutaneous, and visceral leishmaniases are caused
by different Leishmania species and affect several million
individuals worldwide [1–3]. The treatment of leishmaniasis
in endemic areas relies on chemotherapy, and in several parts
of the world the mainstay remains the pentavalent antimony
(SbV)–containing drugs Pentostam and Glucantime. Second-
line drugs such as pentamidine or liposomal amphotericin B
are less useful owing to problems associated with either
toxicity or cost [2]. The proven clinical efﬁcacy of the oral
drug miltefosine was a major breakthrough for anti-Leishma-
nia chemotherapy and has become the ﬁrst-line drug in
north-east India where unresponsiveness to SbV drugs in
visceral Leishmania donovani is epidemic [4,5]. Unresponsive-
ness to SbV may be due to several factors, but in one study it
was shown that unresponsiveness in L. donovani isolates was
correlated with decreased susceptibility to SbV when tested
in an intracellular in vitro assay [6]. The emergence of SbV-
resistant parasites was expected in north-east India because
of the high endemicity of the parasite, the high proportion of
treated individuals, and the nature of the anthroponotic (man
to man) transmission cycle of L. donovani [1].
Both cutaneous and visceral forms of leishmaniasis are
endemic in different parts of Iran [7,8]. Anthroponotic
cutaneous leishmaniasis (ACL) caused by Leishmania tropica
and zoonotic cutaneous leishmaniasis (ZCL) are endemic in
many parts of Iran with a high incidence rate [9–12].
Glucantime is the ﬁrst-line drug for the treatment of all
forms of leishmaniasis in Iran. Patients with cutaneous
leishmaniasis (CL) lesions not responding to SbV treatment
have been reported [13], and these patients may require
alternative treatments. In 2002, an outbreak of ACL occurred
in Mashhad, north-east Iran, where almost 4,900 CL cases
have been detected by clinical and parasitological methods
(Khorassan Health Centers Reports 2000–2002). The results
of a cross-sectional study in this area showed that 94.2% of
isolates were L. tropica [14] and that almost 12% of the
patients did not respond to treatment with meglumine
antimonate (M. Mohebali, unpublished data). The objective
of this study was to determine whether clinical unresponsive-
ness to SbV in patients with ACL was correlated to parasites
with decreased susceptibility to SbV.
Methods
Study Design
Patients of between 20 and 45 y of age and residing in
Mashhad (an endemic area of ACL) who were willing to
participate were included in the study. The study was
approved by the Institutional Ethical Committee of the
School of Public Health and Institute of Public Health
Research, Tehran University of Medical Sciences. CL was
conﬁrmed by parasitological procedures, including observa-
tion of the amastigotes under light microscopy with high
magniﬁcation (31,000) and their cultivation in speciﬁc
culture media. Pregnant and lactating patients were excluded
from this study. Patients with previous CL history were also
excluded. From the 248 patients that were initially included
in the study, 185 isolates of Leishmania species were collected
from skin lesions (Figure 1). Lesions were in general non-
ulcerative (71%), and 63% of patients had single lesions.
Patients were treated according to the physician’s and/or the
patient’s decision either systemically, intralesionally, or, for a
small number of patients, with both regimens (Figure 1). The
national protocol for the treatment of ACL is systemic SbV
(20 mg/kg/d for 14 d), and noncompliance to this protocol is
mostly induced by the patient’s wish. No interference with
common practice implemented in the treatment strategy was
made through this study. Successful treatment was deﬁned as
complete re-epithelialization of all lesions with no relapse
within 6 mo of follow up. Parasites were also collected from
skin lesions which did not respond to treatment (n ¼ 20, see
Figure 1). Patients were classiﬁed as nonresponders when
they presented lesions at a 24-mo follow up. These patients
were treated with a second course of Glucantime.
Figure 1. Treatment Outcome and Parasite Isolation
Parasites were isolated from 185 patients with suspected ACL prior to treatment. Patients were included in three forks of treatment, and 20 patients did
not respond to therapy. Parasites from these nonresponders were also isolated.
DOI: 10.1371/journal.pmed.0030162.g001
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Drug Resistance in Leishmania tropicaParasites and Culture
Parasites were isolated from skin lesions as described [15]
and grown in NNN medium and subcultured in RPMI 1640
medium supplemented with 15% fetal calf serum (FCS).
Identiﬁcation of Leishmania parasites was attempted by PCR
typing using a random ampliﬁed polymorphic DNA (RAPD)
technique [8,14] following a published protocol [16]. Selected
primers for these studies were A4, 59AATCGGGCTG; AB1–
07, 59GGTGACGCAG; 327, 59ATACGGCGTC; and 329,
59GCGAACCTCC. Species identiﬁcation of Leishmania iso-
lates was further studied by sequencing the PTR1 gene, a
metabolic gene involved in pterin and folate metabolism in
Leishmania [17,18]. The PTR1 coding region of each ﬁeld
isolate was ampliﬁed by PCR using the primers
59CTGCTCCGACCGTGCC and 59CCCGGGTAAGGCTG
TAGC. The expected 800-bp ampliﬁed product was puriﬁed
and sequenced. The sequences were compared with sequen-
ces of L. tropica, L. major, L. tarentolae, and L. donovani reference
isolates using the ClustalW program (http://www.ebi.ac.uk/
clustalw) and the Molecular Evolutionary Genetics Analysis
(MEGA3) software (http://www.megasoftware.net).
Pulsed-Field-Gel Karyotyping
Agarose blocks containing Leishmania cells were prepared
as described [19]. Brieﬂy, cells were resuspended in HEPES
buffer at a density of 1 3 10
8 cells/ml and mixed with low-
melting-point agarose. Cells were lysed in the presence of 0.5
M EDTA (pH 9.5), 1% SLS, and proteinase K, and the
chromosomes of Leishmania cells were resolved by a BioRad
(Hercules, California, United States) contour-clamped homo-
geneous electric ﬁeld (CHEF) mapper for separating 0.2–2.0-
Mbp DNAs over a period of 28 h. Chromosomes were
revealed by ethidium bromide staining.
Susceptibility Testing
Mouse peritoneal macrophages. The macrophages of
peritoneal ﬂuid of BALB/c mice were collected and resus-
pended at 5 3 10
4/ml in RPMI 1640 supplemented with 15%
FCS, as described by others [6]. Cells were plated in eight-
chamber LabTek tissue-culture slides, and adherent macro-
phages were infected with late-logarithmic promastigote
parasites at a parasites-to-macrophage ratio of 4:1. After 2
h of incubation at 34 8C, free promastigotes were removed
and Glucantime was added. Each 5-ml ampoule of Glucan-
time contained 1.5 g meglumine antimoniate corresponding
to 0.405 g of pentavalent antimony. The tissue-culture slides
were incubated for 3 d, fresh Glucantime was added, and the
slides were incubated for an additional 72 h. The slides were
ﬁxed and stained with Giemsa [20]. Three slides were used for
each isolate. The percentage of infected macrophages and the
number of parasites per infected cell were evaluated by
microscopic examination of at least 100 macrophages. The
EC50 is deﬁned in this study as the concentration of
meglumine antimoniate that reduces the survival of Leishma-
nia parasites by 50%. These studies were approved by the
Animal Committees of the School of Public Health and
Institute of Public Health Research, and of the Center for
Research and Training in Skin Diseases and Leprosy, Tehran
University of Medical Sciences.
THP1 cell line. A number of sensitive and resistant
parasites, as determined by the mouse peritoneal macrophage
assay, were selected and used for the in vitro susceptibility
assay in the human monocyte cell line THP1 [21]. Recombi-
nant parasites were produced by transfection of the
Leishmania isolates with the ﬁreﬂy luciferase–containing
vector pSP1.2 LUC aHYGa [22] and were used to infect
THP1 cells (ratio 20:1) stimulated with phorbol myristic
acetate (PMA) as described [21]. Luciferase activity was
measured after 5 d of incubation in the presence of
Glucantime. Previous in vitro and in vivo work demonstrated
an excellent correlation between luciferase activity and
parasite number [20,21,23]. Susceptibility to trivalent anti-
mony was also determined in the promastigote stage of the
parasites, as described elsewhere [24] by measuring the
optical density of cultures at 600 nm.
Results
Unresponsiveness to Glucantime Treatment
Out of the 248 patients with parasitological proven CL and
with no previous history of Glucantime treatment, we grew
185 parasite isolates. The patients were treated either systemi-
cally or intralesionally. The two treatment regimens appeared
to be equally effective, with no relapse within the ﬁrst 6 mo
after treatment for the majority of patients (Figure 1). Two
responding patients showed relapse after 12 mo, although no
work was carried out to determine whether this represented a
true relapse or a new infection. Ten patients were ﬁrst treated
intralesionally, but owing to the pain induced by intralesional
injection, the patients preferred to receive systemic SbV and
therefore received a round of systemic SbV (Figure 1). Overall,
10.8% of patients (20 out of 185) did not respond to the ﬁrst
course of SbV treatment (Figure 1). A slightly higher, but not
signiﬁcant, proportion of nonresponding patients were seen
in the groups receiving intralesional treatment (Figure 1).
The goal of this study was to determine whether unre-
sponsiveness to Glucantime is due to the presence of resistant
parasites. The EC50 of the 185 isolates derived from lesions
before initiation of therapy was ﬁrst measured using the
peritoneal mouse-derived macrophage model [6]. Similar
infection rates were observed between parasites derived from
responsive (91.3 6 12.9 amastigotes/100 untreated macro-
phages) and unresponsive (83.7 6 8.0 amastigotes/100 un-
treated macrophages) patients. The results showed a strong
correlation between the clinical outcome and susceptibility
values. Indeed, the 165 patients who responded to SbV
treatment were infected with parasites with EC50 values of
less than 10 lg/ml (p , 0.001, as determined by the Mann-
Whitney test) (Table 1). In contrast, the 20 primary non-
responders were infected with parasites that had considerably
Table 1. Relationship between Clinical Outcome and In Vitro
Susceptibility Testing in Mouse-Derived Macrophages of Leish-
mania Cells Isolated from Patients with ACL
Clinical Outcome In Vitro Susceptibility Tests EC50 (lg/ml)
a
Healing (n ¼ 165) ,10 (n ¼ 165); mean ¼ 4.6 6 1.6
Non-healing (n ¼ 20) 10–25 (n ¼ 16), mean ¼ 18.9 6 3.2;
.40 (n ¼ 4), mean ¼ 48.6 6 1.9
aValues are shown as lg of SbV/ml.
DOI: 10.1371/journal.pmed.0030162.t001
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Drug Resistance in Leishmania tropicahigher EC50 to SbV ratios. These parasites could be identiﬁed
as falling into two groups: those parasites with intermediate
EC50 values ranging from 10 to 25 lg/ml and those with EC50
values greater than 40 lg SbV/ml (Tables 1 and 2). These EC50
values were obtained from strains isolated prior to the
initiation of treatment, but the EC50 values of parasites from
unresponsive patients were similar regardless of whether the
parasites were isolated pre- or posttreatment (unpublished
data). Parasites derived from unresponsive patients were, on
average, at least four times less susceptible than parasites
from responsive patients (p , 0.01, as determined by the
Mann-Whitney test (Table 1).
Characterization of Parasites
Further characterization of the parasites was warranted
since the observed differences in susceptibility values could
be due to the emergence of resistant parasites or to varying
clones or species with different intrinsic susceptibilities (see,
for example, [25]). Thirty-one strains (the 20 nonresponsive
and 11 responsive isolates) were characterized at the
molecular level by a number of techniques. Attempts to
identify the species of parasite were initially carried out using
PCR typing by a RAPD technique [14]. Unambiguous
identiﬁcation was reached for 18 of the 31 strains, but for
the remaining isolates, identiﬁcation of the species was only
tentative (Table 2). Sequencing of locus is a powerful strategy
for microbial species identiﬁcation, and sequencing of the
PTR1 gene was found to be useful for molecular identiﬁca-
tion of Leishmania species (M. Ouellette, unpublished data).
Comparative analysis of the PTR1 sequences of the 31 isolates
showed that most of the selected strains could be identiﬁed as
L. tropica, with three isolates being identiﬁed as L. major
(Figure 2). This locus-sequence technique could also resolve
any ambiguous results of the PCR-RAPD assay (Table 2).
A pulsed-ﬁeld-gel electrophoresis (PFGE) technique was
used as a second strategy to characterize the 31 selected
isolates, and the goal was to ﬁnd susceptible and resistant
parasites with similar karyotypes. Using this strategy, the 31
studied strains were categorized into four PFGE-distinct
groups, the most different being group IV which comprised
the L. major strains (Figure 3). Groups I to III consisted of L.
tropica, and differences in karyotype were small with one to
two bands differing (Figure 3). For L. tropica isolates belonging
to Groups I, II, and III, we had a representative isolate that
was susceptible, one that was resistant to intermediate levels
of SbV, and one that was highly resistant (Figure 3; Table 3).
Several susceptible and non-susceptible isolates are genet-
ically closely related (Figure 3), and further measurements of
their susceptibility value using the more tractable system of
the THP1 cell line and of luciferase-expressing parasites was
warranted. The latter system is a convenient and rapid
quantitative method to look at intracellular growth of
Table 2. EC50 Determination and Characteristics of Selected Leishmania Isolates
ID Number CHEF Group Species Identification
(RAPD-PCR)
Species Identification
(PTR1 Sequencing)
Clinical Outcome In VitroEC50
(lg/ml) Determination
a
665 II L. major? L. tropica Healing 2.2 6 0.3
848 II L. tropica L. tropica Healing 3.2 6 0.3
175 III L. tropica L. tropica Healing 3.5 6 0.3
384 I L. tropica L. tropica Healing 3.8 6 0.8
936 III L. tropica L. tropica Healing 4.6 6 1.1
460 II L. tropica L. tropica Healing 5.1 6 0.3
482 I L. tropica L. tropica Healing 5.9 6 0.8
248 IV L. major? L .major Healing 6.5 6 0.5
749 IV L. major L .major Healing 6.7 6 0.3
527 III L. tropica? L. tropica Healing 6.7 6 1.3
375 III L. tropica L. tropica Healing 9.7 6 2.2
253 I L. tropica L. tropica Non-healing 13.2 6 1.6
907 III L. tropica? L. tropica Non-healing 13.8 6 2.4
178 III L. tropica L. tropica Non-healing 14 6 0.5
932 I L. tropica L. tropica Non-healing 16.7 6 1.1
105 IV L. major L. major Non-healing 17 6 0.8
867 II L. tropica L. tropica Non-healing 17.8 6 0.3
288 III L. tropica? L. tropica Non-healing 18.6 6 0.8
904 II L. tropica? L. tropica Non-healing 19.7 6 0.8
422 II L. major? L. tropica Non-healing 20.2 6 4.3
338 III L. tropica? L. tropica Non-healing 20.8 6 3
131 III L. tropica? L. tropica Non-healing 21.3 6 0.5
940 II L. major? L. tropica Non-healing 21.6 6 3.8
467 III L. tropica L. tropica Non-healing 21.9 6 2.2
421 I L. tropica? L. tropica Non-healing 22.1 6 1.1
514 III L. tropica? L. tropica Non-healing 22.1 6 1.6
500 II L. tropica L. tropica Non-healing 23 6 3
878 II L. tropica L. tropica Non-healing 46.7 6 1.3
670 I L. tropica L. tropica Non-healing 47.5 6 1.3
439 I L. tropica L. tropica Non-healing 49.4 6 2.4
827 III L. tropica? L. tropica Non-healing 51 6 3.5
A question mark indicates ambiguity.
aAs determined using the intracellular mouse-derived macrophages. Expressed as lg SbV/ml.
DOI: 10.1371/journal.pmed.0030162.t002
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Drug Resistance in Leishmania tropicaparasites [20]. The ﬁreﬂy luciferase gene as part of the
Leishmania expression vector pSPaHYGa [22] was introduced
in L. tropica strains by electroporation. Transfectants resistant
to hygromycin were selected and were shown to express the
ﬁreﬂy luciferase. These transfectants were used to infect the
THP1 cell line, and EC50 values in the presence of Glucantime
were determined by measuring luciferase activity (Figure 4).
The values obtained with this rapid assay were in excellent
agreement with the values obtained using the mouse macro-
phages assay and Giemsa staining (Tables 2 and 3). It was not
possible to use the luciferase marker with L. major, as the
available L. major Iranian isolates are intrinsically resistant to
hygromycin with an EC50 of .5 mM—hence precluding the
selection of transfectants using hygromycin.
Properties of the resistance phenotype. It is suspected that
long-term in vitro growth of patient-derived resistant para-
sites may lead to a loss of the resistance phenotype, although
antimony resistance is stable in parasites selected for
resistance in vitro [26,27] or in Indian ﬁeld isolates [28].
The 20 L. tropica strains with intermediate or high resistance
levels to Glucantime were grown for at least 20 passages as
promastigotes in the absence of drug selection (except for
hygromycin B to keep the luciferase marker). A susceptibility
assay was carried out in the THP1 cell line, and no decrease in
the EC50 was observed in these cells compared to cells with a
minimum number (between three and ﬁve) of passages (Table
3; unpublished data). While SbV is the drug used against
leishmaniasis, there is a general consensus that the active
form of the metal is SbIII (reviewed in [29]). This metal
reduction could occur both in the macrophage [30,31] and in
the parasite [32–34]. Promastigote cells selected for SbIII
resistance are cross-resistant to SbV as intracellular parasites
[27,31]. Leishmania parasites selected for SbV resistance are
sometimes [35,36], but not always [32], cross-resistant to SbIII.
We therefore tested the level of susceptibility of the
promastigote stage of ACL clinical isolates to SbIII. In some
groups of strains (e.g., PFGE group I), the intracellular EC50
values toward SbV, and SbIII cross-resistance values as
determined in promastigotes, did correlate (Table 3). For
other strains of different PFGE groups, however, there was a
lack of correlation between intracellular SbV and promasti-
gote SbIII susceptibilities. The L. major isolates studied were
completely insensitive to SbIII as promastigotes (Table 3).
Several potential mechanisms of resistance to antimonials
have been proposed based on work on cells selected for
resistance in vitro (reviewed in [29]). Intracellular thiols
including the glutathione-spermidine conjugate trypano-
thione [26,37] are important molecules involved in resistance.
It has been shown that inhibiting glutathione biosynthesis, a
backbone of trypanothione, can lead to antimony resistance
reversal in vitro in promastigotes [26] or intracellular
amastigotes [27], as well as in vivo [38]. We have shown that
Figure 2. Phylogenetic Analysis of Leishmania Isolates Responsible for
ACL by Comparing the Sequences of PTR1
The PTR1 gene was sequenced in 31 Iranian isolates and control L. major
cells (LV39; Friedlin), L. donovani 1S2D, L. infantum (MHOM/67/ITMAP-
263), L. tropica ATCC50129, and L. tarentolae TarII. Strain 848 is identical,
as determined by RAPD-PCR, to L. tropica MHOM/IR/99, and strain 749 is
identical to L. major MHOM/IR/75/ER. Strains 444 and 454 were
Leishmania parasites isolated from dogs in Iran. The sequences were
compared and clustered using the Molecular Evolutionary Genetics
Analysis (MEGA3) software.
DOI: 10.1371/journal.pmed.0030162.g002
Figure 3. Karyotypes of Iranian Leishmania Isolates as Determined by
PFGE
Leishmania cells lysed in situ in agarose blocks were run in agarose gels,
and chromosome-sized bands were resolved by CHEF electrophoresis. I,
II, III, and IV represent the various karyotypes, and cardinal numbers
represent the identification number of Leishmania isolates (see Table 2).
M indicates S. cerevisiae molecular-weight maker (BioRad).
DOI: 10.1371/journal.pmed.0030162.g003
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Drug Resistance in Leishmania tropicabuthionine sulfoximine (BSO), an inhibitor of c-glutamylcys-
teine synthetase (which is the rate-limiting step of glutathione
biosynthesis), can reverse resistance to Glucantime not only
in the highly resistant L. tropica isolate 827 (Figure 5; Table 2)
but also in three other studied resistant strains with ID Nos
439, 670, and 878, respectively (unpublished data).
Discussion
Antimonials have been the pillar of anti-Leishmania chemo-
therapy for more than 60 y. Despite its toxicity, the drug has
remained effective and available in endemic countries
although, in order to maintain its effectiveness, the drug
concentration and duration of therapy have had to increase
over the years [39], suggesting that the parasites have been
slowly acquiring mutations leading to reduced susceptibility
to the drugs. However, other factors, such as reduced ability
of the human-host immune system to ﬁght the parasites,
pharmacological deﬁciencies, or under-treatment, could also
lead to treatment failure [40,41]. In the 1990s, the failure of
SbV treatment in north-east India became epidemic [4], and
in one study it was shown that part of the unresponsiveness in
the L. donovani Indian isolates was due to parasites with
decreased susceptibility to SbV when tested as intracellular
parasites [6]. Indeed, there is a general consensus that to be of
some relevance, in vitro susceptibility testing has to be done
with intracellular stages of Leishmania [42–44]. While unre-
sponsiveness to SbV is high in part of India, it is still an
effective treatment in several other parts of the world, and it
is still the drug of choice for the treatment of ACL in Iran
[13].
The ACL cycle caused by L. tropica is well established in Iran
[7,11,45], and this human-to-human mode of transmission
could facilitate the emergence of parasites less susceptible to
Table 3. Susceptibility of Parasites to Glucantime and SbIII
ID Number CHEF Group Clinical Outcome EC50 Glucantime (lg/ml)
a SbIII Susceptibility (lM)
b
482 I Healing 2.6 6 0.5 ,60
253 I Non-healing 14 6 0.8 .160
670 I Non-healing .40 .160
253-rev
c I1 4 . 3 6 0.5 ND
670-rev I .40 ND
848 II Healing 4.9 6 0.3 ,60
867 II Non-healing 18.9 6 1.3 ,60
940 II Non-healing .40 ,60
175 III Healing 2.2 6 0.3 ,60
338 III Non-healing 16.2 6 1.4 .160
827 III Non-healing .40 ,60
338-rev III 15.9 6 1N D
827-rev III .40 ND
749 IV Healing ND .160
105 IV Non-healing ND .160
aAs determined by the THP1 intracellular assay. Expressed as lg SbV/ml.
bAs determined with the promastigote stage of the parasite.
crev indicates parasites grown in the absence of drugs for 20 passages as promastigotes, and resistance was tested as intracellular parasites.
ND, not determined.
DOI: 10.1371/journal.pmed.0030162.t003
Figure 4. Parasite Susceptibility to Glucantime in the THP1 Cell Line
Parasites expressing the firefly luciferase were used to infect THP1, and
the levels of parasites surviving Glucantime treatment were calculated by
measuring luciferase activity expressed as percentage relative light unit
(RLU %). The average of two independent experiments performed in
duplicate is shown. Open circles indicate strain 175 (sensitive); open
triangles indicate strain 467 (intermediate resistance); and open squares
indicate strain 827 (high resistance).
DOI: 10.1371/journal.pmed.0030162.g004
Figure 5. Reversal of Antimony Resistance in Intracellular ACL Strains
Using BSO
The glutathione-specific inhibitor BSO (5 mM) abrogated resistance in
the Glucantime-resistant strains 439, 670, 827, and 878. Only the result
for strain 827 (expressing the firefly luciferase) is shown, which
represents an average of two duplicate experiments. Open squares
indicate strain 827; filled squares indicate strain 827 and BSO.
DOI: 10.1371/journal.pmed.0030162.g005
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Drug Resistance in Leishmania tropicaSbV. Indeed, anecdotal evidence indicates that an increasing
proportion of patients with ACL are failing SbV therapy. In
order to test whether resistant isolates exist, we measured the
EC50 of 185 isolates derived from patients before initiation of
treatment. We found a strong correlation between the clinical
outcome and the susceptibility levels of parasites (Table 1).
This correlation was highly signiﬁcant (p , 0.01) as
determined by a series of statistical analyses. L. major isolate
No. 105, a species usually associated with ZCL, was also found
to be resistant to Glucantime (Table 2). A correlation between
susceptibility testing and clinical outcomes, with few outliers,
has also been found for L. donovani isolates [6] and for L.
infantum [44]. For the L. infantum isolates, however, this
correlation stands only for the short-term outcome and not
for the longer-term outcome, possibly because the majority of
patients included in this study were infected with HIV-1 [44].
The parasites derived from non-healing patients were
characterized and were found to be closely related to
parasites derived from susceptible patients (Figure 3; Table
2). To our knowledge, this is the ﬁrst detailed demonstration
that resistant and sensitive clinical Leishmania isolates are
related and the ﬁrst proven case of ACL treatment failure due
to resistant parasites, strongly pointing to acquired drug
resistance in these isolates.
Susceptibility data suggest at least two resistance mecha-
nisms, one leading to an intermediate level of resistance (as
found in the majority of the isolates) and the other leading to
a high level of resistance. It remains to be explored whether
intermediate resistance is a necessary step before achieving
high resistance, or whether the mutations arise independ-
ently. If resistance was at one point associated with a ﬁtness
cost, it would appear that the parasite did compensate for it,
since its infectiousness to macrophages was found to be
comparable to its survival as an intracellular parasite.
Whatever the nature of the mutation, it appears (at least in
some cells) to be stable, since parasites grown for more than
20 passages in the absence of drugs still kept the same level of
resistance. Similar conclusions about infectivity of resistant
cells and stability of the resistance phenotype were also
reached for L. donovani clinical isolates [28,46]. The stability of
the resistance phenotype would rule against gene-ampliﬁca-
tion events, as amplicons present in drug-resistant parasites
are usually rapidly lost during growth of the parasites in the
absence of selection [19]. Consistent with this premise, we
failed to detect gene ampliﬁcation in the resistant isolates (R.
Hadighi and M. Ouellette, unpublished data) when using a
number of techniques enabling the detection of ampliﬁed
genes [47]. Modulation in RNA levels are also commonly
associated with drug resistance [27,48–51]. These changes in
RNA expression are usually stable, and this type of change or
a point mutation could possibly explain the resistance
phenotype found in resistant isolates.
To correlate treatment outcome with susceptibility of the
parasites, we used two models, i.e., the mouse-derived
macrophages and Giemsa staining and a human monocyte
cell line (THP1) and luciferase-expressing parasites. An
excellent correlation was found between the two models
(Tables 2 and 3). The second assay system has obvious
advantages as it neither requires animals nor involves the
labor-intensive parasite staining and counting [20,21]. The
required transfection of the parasites is now a relatively
straightforward technique that does not appear to modify the
properties of the parasite—at least the ones related to
macrophage infection and drug susceptibility (Tables 2 and
3). Comparable results of susceptibility testing using trans-
fected parasites were also obtained for L. donovani ﬁeld
isolates [28,46,52]. The susceptibility of promastigotes to SbIII
did not correlate well with intracellular SbV susceptibility
data (Table 3). This could be due to either different resistance
mechanisms, some giving cross-resistance to SbIII, or to
varying levels of intrinsic resistance. In addition, this simpler
SbIII-susceptibility assay could not be used to predict clinical
outcome.
Our report describes, in detail, several L. tropica and one L.
major isolates that appear to have acquired mutations leading
to decreased susceptibility to SbV and to unresponsiveness
towards clinical therapy. It is salient to point out that four out
of the 20 primary unresponsive patients responded to a
second course of Glucantime treatment. All four harbored
parasites with intermediate levels of resistance (EC50 10–25
lg/ml). The next challenge will be to determine the exact
molecular mechanisms of resistance. It is possible that, as in
the in vitro isolates, thiols are important for the resistance
phenotype (Figure 5). Indeed, preliminary results suggest that
glutathione levels are higher in some resistant isolates (G. Roy
and M. Ouellette, unpublished data). This suggests a strategy
of using drug combinations to reverse drug resistance in the
ﬁeld. Ongoing studies should lead to a better understanding
of the molecular mechanisms of antimony resistance in ﬁeld
isolates.
The equation between chemotherapeutic resistance (either
in infectious diseases or oncology), as determined by in vitro
testing, and treatment failure is intuitively expected but in
some occasions this is still unclear. For example, in the case of
pneumonia caused by Streptococcus pneumoniae, often in vitro
ﬁndings do not appear to be predictive of in vivo outcome,
except with the most highly resistant bacteria (reviewed in
[53]). However, several reports indicate that an increase in
drug resistance is associated with an increased treatment
failure (reviewed in [54,55]). Failure in SbV treatment in
Leishmania has been attributed to several factors other than
resistant parasites, including host immunological status,
suboptimal treatment, and pharmacokinetic properties
[40,41], but it is now clear that an increase in resistance can
lead to treatment failure for both visceral leishmaniasis [6]
and CL. Future work should lead to a precise understanding
of the resistance mechanisms in ﬁeld isolates, which should
lead to strategies for rapidly diagnosing resistance in order to
improve the clinical management of leishmaniasis.
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Patient Summary
Background. Leishmaniases are a group of diseases caused by different
species of the Leishmania group of parasites. The diseases are common
in many tropical and subtropical areas, where patients are infected
through the bite of sandflies that had previously bitten an infected
animal or human. The most common form of the disease is cutaneous
leishmaniasis, characterized by skin ulcers that take months to heal and
often leave ugly and disabling scars. They can also lead to secondary,
more dangerous, infections. In most parts of the world, so-called
pentavalent antimonials are the drug of choice. Over the past few years,
these drugs are becoming less and less effective against the disease,
with increasing numbers of patients not responding, showing only
partial recovery, or needing higher doses of the drugs to get better. A
few additional drugs are now available and are being developed, but
some are expensive and others have serious side effects.
Why Was This Study Done? There are several possible explanations as
to why the pentavalent antimonials are becoming less effective:
parasites could have become increasingly resistant to the drugs, the
patients’ immune systems could have become weaker over time, or
different strains of parasites against which the drugs are not as effective
could be responsible for more of the recent cases. It is important for
health officials to know which of these apply when they decide on
strategies to improve the situation. Results from north-east India, where
L. donovani is the predominant cause of the disease, suggest that the
parasites are becoming resistant. The scientists who did this study
wanted to find out which of these possibilities might be true in Iran, a
country in which cutaneous leishmaniasis is common.
What Did the Researchers Do and Find? They discussed the study with
many patients with cutaneous leishmaniasis in Mashad, an area in Iran
where the disease is common. Of those patients, 248 were suitable and
agreed to participate. The researchers then isolated parasites from 185
different ulcerous wounds, including 20 from patients who did not
respond well to treatment with pentavalent antimonials. They studied
these parasites in various ways. They found that all of the parasites from
the 20 nonresponsive patients were either partially or fully resistant to
the drugs, meaning that either higher doses of drugs were necessary or
that even very high doses could not kill the parasites. They then wanted
to know which Leishmania species the responsive and nonresponsive
parasites belonged to. To answer this question, they determined the
genetic code for one specific gene which is known to have different
versions in different species. This showed that 19 of the unresponsive
isolates belonged to L. tropica and one to L. major. Two of the responsive
isolates belonged to L. major, with the other nine belonging to L. tropica.
Among the L. tropica isolates, the responsive and nonresponsive isolates
showed some similarities at a broader genetic level.
What Do These Findings Mean? The results show that L. tropica
parasites can become resistant to pentavalent antimonials. They also
suggest that such resistant strains are largely responsible for the
decreased effectiveness of these drugs against cutaneous leishmaniasis
in Iran. This means that Iran and other countries where resistance is
becoming more common need to develop treatment strategies for
patients who do not respond to pentavalent antimonials. For
researchers, the goal is to identify the molecular mechanisms underlying
drug resistance so that they can be taken into account when advising on
alternative therapies and developing new drugs against the leishma-
niases.
Where Can I Get More Information Online? Here are listed several Web
sites with information on leishmaniasis.
World Health Organization:
http://www.who.int/leishmaniasis/en
MedlinePlus:
http://www.nlm.nih.gov/medlineplus/leishmaniasis.html
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202733.html (for a
description on meglutime antimoniate)
Wellcome Trust Sanger Institute:
http://www.sanger.ac.uk/Projects/L_major
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